Eli Lilly followed Novo Nordisk with the GLP-1 receptor agonists for weight loss, as their medicine, Mounjaro, was approved for weight loss in the UK in November 2023
The general adult weight-management indication includes patients with an initial: BMI of 30 kg/m2 or above, or BMI from 27 kg/m2 to below 30 kg/m2 with at least one weight-related health condition Relevant conditions may include: high blood pressure abnormal cholesterol levels obstructive sleep apnoea cardiovascular disease prediabetes type 2 diabetes Meeting these general criteria does not guarantee that treatment will be prescribed
Regular monitoring lets healthcare providers catch side effects early
In this case, it is noteworthy that the GLP-1 agonist group had no worse visual outcomes compared to the acetazolamide monotherapy group across all primary outcome measures despite the increased risk due to their higher baseline BMI, the researchers wrote in their paper
Both semaglutide tablets and injections have demonstrated effectiveness in aiding weight loss, with injectables slightly outperforming oral forms in specific scenarios
This test assesses the acid/base balance to ensure minimal irritation upon injection
